

Personalized Health and Related Technology (PHRT)
Partnership Agreement
2020 – 2024

November 2020

Table of Contents

1.	Purpose	3
2.	Partners	4
3.	Organisation	5
3.1.	Governing Bodies of the Partnership	5
3.1.1.	Strategic Committee	5
3.1.2.	Executive Committee	8
3.1.3.	Review Panel	12
3.1.4.	Committees for Specific Tasks	13
3.2.	Office	14
4.	PHRT Projects	15
5.	Governance	21
5.1.	Financing	21
5.2.	Power to Sign	22
5.3.	Rights to Intangible Assets Research Results	23
6.	Final Provisions	25

Preamble

Life science research currently undergoes a drastic revolution. Today's medicine is being ultimately transformed into "individualized medicine": in essence, a person's unique biological makeup will guide decisions on how to maintain and restore his or her health. The Strategic Focus Area Personalized Health and Related Technologies (PHRT) aims at contributing cutting-edge research to this worldwide endeavour. To this end, the ETH Domain initiative is being coordinated with universities, hospitals and other initiatives in Switzerland, notably the Swiss Personalized Health Network (SPHN).

ETH Zurich, Empa, EPF Lausanne and the Paul Scherrer Institute (PSI) are the legitimate partners ("Partner(s)") of the Strategic Focus Area Personalized Health and Related Technologies (PHRT).

Legally speaking, PHRT has the form of a "simple society". ETH Board approved a total of CHF 100 million for the period 2017-2024 in two phases. The present Partnership Agreement is based on the agreement of the first phase and sets the frame for a smooth implementation of the PHRT program.

The participating institutions strive to achieve the highest scientific quality in the field of personalized health including related technologies and, through their collaboration within the framework of PHRT (and SPHN), establish for themselves a worldwide reputation of excellence. To this effect, they will support this program with scientific, financial and non-financial contributions and jointly conduct the scientific monitoring of the approved projects and of the PHRT program as a whole.

1. Purpose

Article 1. Purpose

1. This Agreement sets forth the terms of the collaboration between the Partners in the program PHRT to enable them to carry out joint projects in their own interest and enhance their education and research programmes in the field of personalized health. For this purpose, the Partners join together in a “simple society”, that is a Simple Partnership without own legal personality within the meaning of Article 530 et seq. of the Swiss Code of Obligations.
2. In particular, the Partners shall pursue the following objectives:
 - (a) Coordinate the national and international collaboration of the Partners in the field of personalized health;
 - (b) Carry out scientific projects and establish highly specialized development and technology platforms in the field of personalized health;
 - (c) Coordinate the financial contributions for research projects in the field of personalized health;
 - (d) Coordinate the presentation of the Partnership under the name "Personalized Health and Related Technologies (PHRT)";
 - (e) Develop and implement common training programs targeted to young researchers in the field of personalized health;
 - (f) Coordinate and intensify the cooperation with hospitals and the private sector;
 - (g) Secure additional external funding.

Article 2. No Restriction of Autonomy

1. This Agreement shall not affect the autonomy of the individual Partners in research and education. The Partners shall not be subject to any prohibition of competition in any of the areas covered by this Partnership Agreement.

2. Within the framework of PHRT, the participating institutions shall collaborate with one another while respecting their respective legal autonomy.
3. The Partners will be informed of the decisions taken through their delegates in the various Committees, in particular the Strategic Committee (SC) and the Executive Committee (EC). The Office will provide detailed information upon request.

2. Partners

Article 3. Partners

The signatories of this Partnership Agreement shall be the Partners of PHRT. Eawag and WSL can join the partnership anytime on request.

Article 4. Research

The Partners shall support their research groups in their efforts to establish scientific clusters and work on common topics in the field of personalized health. To achieve that, it might be necessary to overcome hurdles and facilitating a smooth collaboration with clinical groups and hospitals. The Partners shall induce their respective research groups to work in such a way as to allow interdisciplinary, in particular medically and clinically relevant research to make significant progress in new areas. For this purpose, PHRT can support financially respective projects. Access to omics or clinical data can be organized as a “clinical service” via the cost category “consumables” in the PHRT budget when data ownership goes, whenever possible, to the ETH Domain partner.

3. Organisation

3.1. Governing Bodies of the Partnership

Article 5. Governing Bodies

The PHRT program shall have the following governing bodies:

- (a) Strategic Committee;
- (b) Executive Committee;
- (c) Review Panel;
- (d) Committees for Specific Tasks.

3.1.1. Strategic Committee

Article 6. Composition, Duties and Powers

1. The Strategic Committee shall be composed of one representative of each Partner. As a rule, it shall be the responsible person (vice president) for research or the Director. In particular cases, a person in a fully empowered similar position.
2. The Strategic Committee shall be the highest governing body of PHRT. In particular, the Strategic Committee meeting shall exercise the following duties and powers:
 - (a) Appoint and dismiss the Chairwoman/Chairman of the Strategic Committee and her/his alternate; as a rule the representative of the leading house where the Office is hosted, shall act as the Chairwoman/Chairman;
 - (b) Approve the business plan, the yearly budget and the yearly management report including accounting;

- (c) Appoint and dismiss the Chairwoman/Chairman and the members of the Executive Committee;
 - (d) Appoint and dismiss the Chairwoman/Chairman of the Review Panel. As a rule, it is the President of the ETH Zurich Research Commission;
 - (e) Approve the Executive Director upon proposal of the Executive Committee;
 - (f) Approve the Bylaws (if any);
 - (g) Approve new PHRT Technology Platforms/Centers/Hubs on request of the Executive Committee;
 - (h) Supervise the activities of the other governing bodies;
 - (i) Promote the PHRT goals (lobbying) in hospitals, industry and politics;
 - (j) Modify the Partnership Agreement;
 - (k) Liquidate the Partnership.
3. The Chairwoman/Chairman of the Strategic Committee and her/his alternate shall be appointed every two years and may be reappointed.

Article 7.

General Strategic Committee meetings

1. The Partnership shall hold no less than one General Strategic Committee meeting in each calendar year.
2. The General Strategic Committee meeting shall be convened by the Chairwoman/Chairman by at least ten days before the meeting in writing specifying the agenda.

Article 8.

Extraordinary General Strategic Committee meetings

The Chairwoman/Chairman may, whenever she/he thinks it fit, convene an Extraordinary General Strategic Committee meeting. A Partner and/or the Executive Committee may request an Extraordinary General Meeting by giving written notice to the Chairwoman/Chairman specifying the agenda and the motions to be considered. It shall be convened following the same procedure as for General Strategic Committee meetings.

**Article 9.
Proceedings**

1. The Chairwoman/Chairman or her/his alternate shall preside as chairperson at the Strategic Committee meeting.
2. Minutes of each Strategic Committee meeting shall be kept. A Partner may request that its motions, including a statement of justification, or its rejection of a resolution be recorded in the minutes.

**Article 10.
Resolutions**

1. In the Strategic Committee meeting, each Partner shall have one vote.
2. Quorum shall be reached if at least half of all members entitled to vote are present.
3. The Strategic Committee meeting shall adopt resolutions with the following majorities:
 - (a) **Unanimity of the votes cast** shall be required for the resolutions concerning
 - (aa) Modifications of the Partnership Agreement;
 - (bb) Liquidation of the Partnership.
 - (b) For all other resolutions of the Strategic Committee meeting, approval by the majority of the Partners shall be sufficient.
 - (c) In case a voting result is a tie, it is the Chairman/Chairwoman who casts the deciding vote.
4. The representative of the Partners whose institution is affected by the decision shall not participate in the voting.
5. Votes shall be cast on a show of hands. Any Partner may request a secret ballot.

6. The Chairwoman/Chairman of the Executive Committee, the Executive Director and the Medical Director shall attend the Strategic Committee meeting in an advisory capacity and with the right to propose motions.

Article 11.
Circular Resolutions

Resolutions may also be adopted by circular letter (email), provided no Partner requests an oral discussion.

3.1.2. Executive Committee

Article 12.
Duties and Powers

1. The Executive Committee shall be the operative body of the Partnership. The Executive Committee shall be responsible for elaborating the scientific strategic planning and for the implementation of the PHRT program as well as for the management of the Partnership. The Executive Committee may also delegate the management of the Partnership to the Chairwoman/Chairman or to the Office. In particular, the Executive Committee shall have the following duties:
 - (a) Establish the business plan formulating (research) priorities to be addressed within the Personalized Health and Related Technologies program;
 - (b) Guarantee a healthy balance between projects with shorter- and longer-term deliverables. Ensure a meaningful balance is reached between projects pertaining to research and those pertaining to infrastructure/platforms;
 - (c) Prepare budgets, the annual account and the annual management report of PHRT to be submitted to the ETH Board;
 - (d) Set up and establish links and collaborations with other similar programs, in particular with SPHN;
 - (e) Prepare and publish call for project proposals and determine the funding level of each call;

- (f) Organize the evaluation process which is delegated to a specific panel (Review Panel)
 - (g) Implement the decisions on funding or rejecting of submitted proposals based on priority scores established by peer review via the Review Panel;
 - (h) Invite experts to propose a business plan for setting up a PHRT Technology Platform/Centre/Hub;
 - (i) Propose to the Strategic Committee new PHRT Technology Platforms/Centres/Hubs for approval based on reviews by external experts;
 - (j) Monitor and control productivity of approved projects;
 - (k) Confirm the members of the Review Panel proposed by its Chairwoman / Chairman;
 - (l) Create and appoint commissions or task forces for specific purposes (e.g. education, data handling) and appoint and dismiss the members of such bodies;
 - (m) Create an Office and select an Executive Director to be proposed to the Strategic Committee;
 - (n) In order to emphasize the importance of cooperation and collaboration between PHRT and industry partners, an “industry liaison person” shall be designated. This task could be assigned to a member of the Executive Committee or to an additional person;
 - (o) Define strategy for a continuation of the ongoing personalized health activities beyond 2024;
 - (p) Represent the Partnership;
 - (q) Ensure the communication within PHRT;
 - (r) All other powers not assigned to another body in this Partnership Agreement.
2. In matters to be submitted to the Strategic Committee meeting, the Executive Committee may present proposals and motions.

Article 13.

Composition | Appointment | Term of Office

1. The Executive Committee shall be composed of
 - (a) eight (8) to fifteen (15) members;
 - (b) at least one (1) researcher from each of the following disciplines: Medicine, Bioinformatics / Computer Science, Physics / Mathematics, Biology, Engineering / Nanotechnology;
 - (c) at least one (1) member of each Partner;
 - (d) the Executive Director (with a right to vote).
2. The members of the Executive Committee shall be appointed by the Strategic Committee meeting upon recommendation of each Partner and in consideration of No. 1b of this Article. They shall be appointed to office for a term of four (4) years and may be reappointed.
3. The Executive Committee shall constitute itself, with the exception of the Chairwoman/Chairman, who is appointed by the Strategic Committee meeting for four years.
4. In case an issue is discussed in which an Executive Committee member has vested interests, she/he will be asked to leave.
5. The Executive Committee can invite external experts to meetings as guests without voting right.

Article 14.

Resolutions

1. Each member of the Executive Committee shall have one vote. The principle of "ad personam participation" shall apply, vote by proxy shall not be allowed.

2. Unless otherwise provided in this Partnership Agreement, the Executive Committee shall take decisions by simple majority of the votes. In case of a tie, the Chairwoman/Chairman shall have the deciding vote.
3. Quorum shall be reached if at least half of all members entitled to vote are present.
4. Resolutions may be adopted by circular letter (email), provided no member requests an oral discussion.

Article 15.
Meetings | Proceedings

1. The Executive Committee shall meet as often as the business may require, **but no less than four (4) times a year.**
2. The meetings shall be called by the Chairwoman/Chairman of the Executive Committee or by the Executive Director on her/his behalf. In addition, every member of the Executive Committee may request the convocation of a meeting by the Chairwoman/Chairman by submitting a written agenda for the meeting to be called.
3. As a rule, at the end of a regular meeting, the date of the next one should be fixed. The agenda is circulated at least four (4) days in advance. In urgent cases, without being required to comply with this notice provision, the Chairwoman/Chairman of the Executive Committee may also call a meeting by written notice or any other adequate means (e.g. by telephone or electronic mail). In such urgent cases, members unable to attend will have the opportunity to contribute to the decisions either during the meeting (discussion and vote by videoconference or telephone), or within 24 hours after the meeting (vote by electronic mail).
4. A member of the Executive Committee may request that an item be placed on the agenda. An inquiry to this effect must be submitted in writing to the Chairwoman/Chairman of the Executive Committee in good time before the invitation to the meeting is issued. Issues of great urgency raised after the invitation to the meeting has been issued may be discussed in the meeting. However, resolutions concerning such issues may only be adopted if all members of the Executive Committee are present and agree about the decision.

5. Only the resolution adopted in the meeting shall be entered in the minutes.
6. In case of circular resolutions (Article 14, No. 4) the decision memorandum shall be confirmed in writing (confirmation by e-mail sufficient) by all members, including the dissenting members, and by the keeper of the minutes.

Article 16.

Participation of Third Parties

1. The Executive Committee may invite interested third parties, e.g. representative of SPHN, hospitals, industry, politics or international research institutions, but also employees of the individual Partners as permanent or non-permanent guests at the Executive Committee meetings. Invited third parties may be excluded from the discussion and voting procedures concerning certain issues. Third parties shall be bound to confidentiality.
2. Permanent and non-permanent guests shall not have the right to vote or move a motion.

3.1.3. Review Panel

Article 17.

Duties and Powers

1. The Review Panel shall be the body to identify the most excellent and forward looking project proposals in the field to advance the leadership of the ETH Domain and more generally Swiss research in personalized health.
2. The selection criteria are scientific potential, originality and quality of the proposal in combination with the potential to bridge from science/engineering to medicine/clinics.
3. The Review Panel categorises all submitted proposals of each project type into A (should be funded), B (funded under particular circumstances) and C (reject).

4. The Review Panel Chairwoman/Chairman informs the Executive Committee about the results of evaluation (for each proposal: category and reviewers comment).
5. The Review Panel Chairwoman/Chairman meets the SPHN IAB to settle disagreements on the evaluation of common “SPHN Driver / PHRT Research” projects;
6. Final decision will be taken by the Executive Committee in agreement with the Review Panel Chairwoman/Chairman.

Article 18.

Composition | Appointment | Term of Office

1. The Review Panel shall be composed of
 - (a) eight (8) to fifteen (15) members;
 - (b) about 50% of the Review Panel members shall be recruited from ETH Domain institutions, the other 50% of its members will be nationally and internationally recruited (i.e. external to the ETH Domain);
2. The Review Panel is chaired by the president of the ETH Zurich research commission. She/he composes the members of the Review Panel according to needs and boundary conditions defined by the Executive Committee.
3. For the evaluation process, the Review Panel is supported by the Office.

3.1.4. Committees for Specific Tasks

Article 19.

Duties and Powers

The Executive Committee may create ad-hoc committees (committees, task forces, working groups) for specific tasks.

3.2. Office

Article 20. Duties and Powers

1. The Office shall be responsible for the daily operations of the Partnership under the supervision and instruction of the Chairwoman/Chairman of the Executive Committee.
2. The Office shall be directed by an Executive Director.
3. The Office shall be integrated at ETH Zurich for the period of this contract in organizational and legal terms. This Partner shall provide the necessary infrastructure for the Office.
4. Salaries and running costs for the Office shall be financed through the PHRT funds provided by the ETH Board.
5. Essentially, the Office shall have the following duties:
 - a) Prepare the agenda for the meetings of the Executive Committee and the Strategic Committee meetings together with their respective Chairwoman/Chairman and record the minutes of the meetings;
 - b) Support the implementation of the resolutions by the Executive Committee;
 - c) Organize, direct and control the daily operations of the Partnership;
 - d) Report, control and prepare the budget;
 - e) Ensure timely and effective information flow between the Office and the Executive Committee, between the members of the Executive Committee and the Strategic Committee meetings;
 - f) Ensure and coordinate the annual financial reporting in cooperation with department of accounting of ETH Zurich;
 - g) Ensure the information flow between PHRT and the Swiss Personalized Health Network (SPHN) initiative as well as to the ETH Board.

4. PHRT Projects

PHRT will realize the goals mandated by the ETH Board by supporting research projects in the field of personalized health and by supporting young scientists at the doctoral and postdoctoral level to embark on a career in personalized health. Specifically, PHRT has created four project categories: (1) education, (2) technology translation (3) technology platforms/centres/hubs and (4) personalized medicine/health research projects (including Driver projects in cooperation with SPHN). Projects involving private hospitals, industrial partners, SME, and others are allowed. However, only ETH Domain research groups are eligible for PHRT funding. Institutions outside the ETH Domain can get funding for “clinical services”.

Article 21.

Clarification of Agreement Requirements for Collaborations

1. In order to ensure an efficient and smooth progress, all PHRT projects must adhere to the ethical, legal and societal frame defined by the guidelines elaborated by SPHN, which have been adopted by PHRT. In particular, **each approved project must submit a copy of all required documents signed**, notably:
 - Data Transfer and Usage Agreement,
 - Data Processing Agreement,
 - Data Sharing Agreement,
 - Publication Agreement,
 - Intellectual Rights Agreement, and/or
 - any other agreements

to the Office **no later than three months after the project start or nine months after project approval at the latest.**
2. In case these documents are not signed in due time, the EC can stop the respective project.

Article 22.
Education Projects

One of the observed limitations in the personalized health research is that most interdisciplinary research approaches rely on the collaboration between experts in individual fields (e.g. medicine and science), each with limited knowledge and understanding of the other field. Therefore, it is essential for young scientists to gain expertise in diverse scientific fields, as an interdisciplinary education influences the way scientists think, approach research questions and set up experiments and it adds to more efficient collaboration across classical disciplines. PHRT strengthens the cross-disciplinary education and training of the next generation of scientists in Personalized Health and Personalized Medicine by offering two different levels of project types, interdisciplinary doctoral projects (iDoc Projects) and Transition Postdoc Fellowships (TPdF Projects).

Article 23.
Interdisciplinary Doctoral Program (iDoc Project)

The PHRT program supports doctoral student positions for students pursuing research projects in the personalized health/medicine field. Student projects are expected to bridge the gap between science/engineering and medicine.

1. Students will be matriculated at EPF Lausanne or ETH Zurich and will be enrolled in one of the established doctoral student programs.
2. Students shall be mentored jointly by investigators from two different disciplines, according to the rules for doctoral studies of EPF Lausanne and ETH Zurich, respectively, one of which shall be medicine.
3. Applications for an iDoc Project shall be submitted according to a call to this effect to the PHRT Office. It shall be recognized as a PHRT iDoc Project when
 - a) the PHRT Review Panel has positively evaluated the proposal (Article 17, No. 3 and 5); and
 - b) the Executive Committee has approved the proposal (Article 12, No. 1g and Article 17, No. 5).
4. iDoc Projects shall be limited in time, to three (3) years as a rule, and may be extended for one (1) year to 48 months in total. They shall remain embedded in organisational and legal terms, and in particular concerning the right of supervision,

at the Partner institution where the doctoral student is enrolled. The main applicant shall be required to report regularly to the Executive Committee on the scientific and financial aspects.

Article 24.
Transition Postdoc Fellow Projects (TPdF Projects)

Postdoctoral fellowships are intended to facilitate the transition of ambitious and motivated young scientists into the interdisciplinary research culture of personalized health research. Research projects must show direct clinical relevance within the field of personalized health and clearly demonstrate a significant extension or transfer of the applicant's research background. Project proposals are expected to contain a link between basic science/engineering and clinical applications.

1. The TPdF candidate shall choose one research group at an ETH Domain institution of a discipline that is complementary to the one of her/his doctoral thesis.
2. The research group will host the Transition Postdoc Fellow and his/her project, allowing the postdoc to unfold and flourish. The Fellow shall be employed by the host Partner institution.
3. Project proposals are accepted from PhD or MD scientists within a maximum period of five (5) years since receiving their highest degree. The relevant dates are the application deadline and the date the degree was awarded.
4. Applications for a TPdF Project shall be submitted according to a call to this effect to the PHRT Office. It shall be recognized as a PHRT TPdF Project when
 - a) the PHRT Review Panel has positively evaluated the proposal (Article 17, No. 3 and 5); and
 - b) the Executive Committee has approved the proposal (Article 12, No. 1g and Article 17, No. 5).
5. TPdF Projects shall be awarded for 24 months (two (2) years) as a rule. They shall remain embedded in organisational and legal terms, and supervision, at the Partner institution where the TPdF is enrolled. The main applicant shall be required to report to the Executive Committee on the scientific and financial aspects.

Article 25.
PHRT Technology Platforms/Centres/Hubs

Technology platforms/centres/hubs aim to generate high quality, high volume individualized molecular profiling data from patients and clinical cohorts. The generated data need to fulfil quality standards required for informing clinical decision-making. Data should be interoperable and made available via the SPHN Data Coordination Center (DCC).

1. The Executive Committee can invite a person or a group to submit a business plan proposal to build up a particular technology as a platform/centre/hub.
2. The business plan shall contain at least the following items:
 - a) objectives and purposed contribution to personalized health / personalized medicine
 - b) clear milestones to build up the platform/centre/hub
 - c) data management (kind of generated data, amount, frequency, processing, analysis, storing, exchange, exploitation, distribution, sharing, archiving, retrieval, ownership, protection, security, etc.) must comply Swiss regulation on data security and the Human Research Act
 - d) plans for data integration across PH platforms/centres/hubs; procedures and structures to cooperate (in particular data exchange etc)
 - e) full cost budget
 - f) governance incl. quality assurance
 - g) mid-term planning (e.g. spin-out)
3. The Executive Committee will set up a monitoring body with various stakeholders that conducts a regular (at least annual) review.
4. A contract will be negotiated to clarify details of the operation mode.
5. A technology platform/centre/hub proposal shall be recognized as a PHRT Technology Platform/Centre/Hub when
 - a) the Executive Committee has positively evaluated the business plan proposal (Article 12, No. 1h and i), and
 - b) the Strategic Committee has approved the proposal (Article 6, No. 2g).

6. PHRT Technology Platforms shall be awarded for 24 to 36 months (two (2) to three (3) years). Project staff shall be hired and employed by the Partner institution. The Technology Platform/Centre/Hub shall be required to submit a progress report every six (6) month and a yearly report to the Executive Committee on the scientific and financial aspects.
7. Details concerning intellectual property rights must be addressed prior to project start.

Article 26.
Technology Translation Projects (TT Projects)

Technology Translation Projects intend to advance innovative technologies pioneered in the ETH Domain for clinical application. It is envisaged that some of these technologies could form the basis for second-generation Technology Platforms/Centres/Hubs.

1. Technology Translation Project proposals are bottom-up projects composed by the main applicant alone or with a consortium.
2. Service contribution from a hospital can be paid based on the respective SNSF regulation. Research contributions from hospitals cannot be funded through PHRT.
3. Applications for a TT Project shall be submitted according to a call to this effect to the PHRT Office. It shall be recognized as a PHRT TT Project when
 - a) the PHRT Review Panel has positively evaluated the proposal (Article 17, No. 3 and 5); and
 - b) the Executive Committee has approved the proposal (Article 12, No. 1g and Article 17, No. 5).
4. TT Projects shall be awarded for 24 to 36 months (two (2) to three (3) years). Project staff shall be hired and employed by the Partner institution. The TT Project shall be required to submit a yearly report to the Executive Committee on the scientific and financial aspects.
5. Details concerning intellectual property rights must be addressed prior to project start.

Article 27.
Personalized Medicine, Personalized Health Research Projects
(PM/PH Research Projects)

Personalized health-related research projects with direct relevance for the patient. These projects can be carried out in collaboration with and jointly funded by complementary programs such as SPHN, or in partnership with clinical centres. Joint PHRT-SPHN projects (“Driver projects”) are funded via this project type.

1. PM / PH Research Project proposals are bottom-up projects of research groups from one or several Partner institutions and SPHN partner institutions (in particular universities and hospitals). They are intended to investigate specific topics of personalized health and/or develop and apply cutting edge technologies relevant for personalized health.
2. Partners acknowledge that faculty members of other Swiss universities as well as the institutions of the ETH Domain are eligible as main applicants. As a rule, only research groups from ETH Domain institutions are funded by the PHRT program, all research groups can receive funding from SPHN according to the SPHN regulations.
3. Applications for a PM/PH Research Project shall be submitted according to a call to this effect to the PHRT Office. It shall be recognized as a PHRT PM/PH Research Project when
 - a) the PHRT Review Panel has positively evaluated the proposal (Article 17, No. 3 and 5); and
 - b) the Executive Committee has approved the proposal (Article 12, No. 1g and Article 17, No. 5); and
 - c) in the case that a PHRT PM/PH Research Project proposed in combined with a SPHN Driver project proposal, the SPHN International Advisory Board and the SPHN National Steering Board have approved the proposal.
4. PM/PH Research Projects shall be awarded for 36 or 48 months (three (3) or four (4) years). Project staff shall be hired and employed by the Partner institution. The PM/PH Research Projects shall be required to submit a yearly report to the Executive Committee on the scientific and financial aspects.
5. Contracts with third parties for PM/PH Research Projects shall be subject to the rules of the hosting institution, taking into consideration the other partners involved.

6. The Executive Committee shall accompany and regularly evaluate the PM/PH Research Projects for conformity with the proposal and with the expectations raised as they were approved. Funding may be adjusted accordingly.

**Article 28.
Evaluation Criteria**

All PHRT project proposals shall be evaluated on the sole criteria of (1) added value to personalized medicine / personalized health and (2) scientific quality. Added value and scientific quality shall be ensured by the Review Panel and the Executive Committee.

5. Governance

5.1. Financing

**Article 29.
Business Year**

The business year of PHRT shall be the calendar year.

**Article 30.
Financing**

1. PHRTs financing shall be ensured by the yearly contributions of the ETH Board. Partner institutions are expected to support the approved PHRT Projects by in-kind contributions to allow for a successful implementation.
2. All PHRT Projects are encouraged to apply for additional funding, be it from competitive research funding institutions (2nd Party Funds from e.g. SNSF, Innosuisse, EU, etc.), the private sector (3rd Party Fund from industry, SME etc.), or others.

3. For the period of this agreement all approved funds will be solely administrated by the Office and the accounting office of ETH Zurich.
4. PHRT funds shall be transferred in tranches to the institutions of the (co-)Principal Investigators.
5. Collaborations with hospitals are encouraged. Partner institutions can pay hospitals contributions if they concern services, in particular “clinical services”.

5.2. Power to Sign

Article 31. Power to Sign

1. Neither individual Partners, nor the governing bodies of the Partnership, nor the Office shall be entitled to enter into agreements and other legally binding arrangements with third parties in the name and for the account of the PHRT Partnership. As an exception, agreements with the ETH Zurich as a host and other Partners (e.g. for releasing PHRT funds, reports etc.) can be jointly signed by the Chairwoman/Chairman of the Strategic Committee, the Chairwoman/Chairman of the Executive Committee or the Executive Director.
2. For the implementation of the approved projects, payments to the individual Partners shall be made in accordance with the regulations of the Partner¹ managing PHRT's finances.
3. The power to sign of the Chairwoman/Chairman of the Executive Committee and of the Executive Director of the Office for management-related expenses (e.g. office materials) shall be as provided in the regulations of the respective Partners employing the persons mentioned.
4. In order to simplify procedures, requests addressed to the PHRT for less than CHF 25'000 can be jointly decided by the Executive Committee Chairwoman/Chairman and the Executive Director. The Executive Committee is informed subsequently about approval or rejection of respective requests.

¹ e.g. Financial Regulations of the ETH Zurich (RSETHZ 245)

Article 32.

Accounting Records, Reporting and Audit

1. The Partners shall keep all accounting records for PHRT, which will be used for the annual financial reporting.
2. For the period of this agreement the Office shall be responsible for the accounting and annual financial reporting of PHRT funds. This task can be mandated to the accounting department of ETH Zurich.
3. The audit of the PHRT program as a whole shall be carried out by the ETH Board. PHRT projects shall be audited by internal or external auditors on a case-by-case decision.
4. The Office reports the annual financial reporting including the auditor's report to the Executive Committee meeting and the ETH Board.
5. The costs for the administration mandate for accounting and reporting are covered by PHRT.

5.3. Rights to Intangible Assets | Research Results

Article 33.

Research Results | Data | Inventions

1. All rights to results generated within a PHRT Project (including intellectual property rights such as inventions and software) shall belong to that Partner that generated the results. Protection and commercialization of such results shall be governed by the respective regulations of this Partner. If more than one Partner have contributed to results, the involved Partners shall agree among themselves upon ownership, rights and strategy of commercialization.
2. The PHRT Projects respect good scientific practices and follow guidelines for research integrity of their Institution and/or of the SNSF.

3. PHRT Partners shall have reasonable access to the results generated within scientific projects for research purposes at no cost.
4. Access to data arising from the activities involved in PHRT Projects for scientific purposes of the PHRT Partners shall be governed according to the FAIR principle and regulated in particular as follows:
 - a) Data shall be recorded, processed and archived according to established standards;
 - b) Data shall be made accessible upon request to all PHRT research groups twelve months after generation and to other interested research groups twenty-four months after generation.
 - c) Results of PHRT Projects shall be made accessible publicly as soon as reasonably feasible.
5. Exceptions have to be approved by the Executive Committee.

**Article 34.
Dissolution**

The Partnership shall be dissolved upon a resolution to that effect by the Strategic Committee meeting.

**Article 35.
Liquidation**

In case of dissolution of the Partnership its assets shall be allocated to the contributing Partners or to the ETH Board.

6. Final Provisions

Article 36.

Duration of Partnership, Amendment

The PHRT program was established in 2017. The first phase lasts from 2017 to 2020, the second phase was approved for 2021 to 2024. Projects of the first phase will be active until 2021 (or even 2022). The present contract shall be amended by mutual agreement in writing between the partners of PHRT. After all activities came to an end, the simple society PHRT will be dissolved (Articles 34 and 35).

Article 37.

Applicable Law

This Partnership Agreement shall be governed by Swiss Law.

Article 38.

Settlement of Disputes

The primary mechanism for the resolution of disputes shall be negotiation within the Partnership. Should this fail to succeed, disputes arising out of or in connection with the present agreement shall be finally settled by the President of the ETH Board.

There exist five (5) specimens of this agreement: one for each Partner, one for the Office

The following documents shall be deemed an integral part of this Agreement:

- Beschluss des ETH-Rats vom 28./29. September 2016: Implementation of Strategic Focus Areas 2017-2020 A) SFA Personalized Health and Related Technologies
- 1st Call for Proposals (published in June 2017)
- Beschluss des ETH-Rats vom 4./5. März 2020: Implementation of Strategic Initiatives 2017-2020 a) Strategic Focus Areas (SFA); Personalized Health and Related Technologies (ETH Zürich)

For the ETH Zurich:

City: Zürich

Date: 20.11.2020

[Signature]

Prof. Dr. Joël Mesot, President

[Signature]

Prof. Dr. Detlef Günther, VP for Research and Corporate Relations

For the EPF Lausanne:

City: Lausanne

Date: 7.1.2021

[Signature]

Prof. Dr. Martin Vetterli, President

[Signature]

~~Prof. Dr. Andreas Mortensen,
VP for Research~~

Prof. Dr. Jan Hesthaven
VP for Academic Affairs

For the Empa - Swiss Federal Laboratories for Materials Science and Technology:

City: Dübendorf

Date: 18.12.2020

[Signature]

Prof. Dr. Gian-Luca Bona, Director



[Signature]
Dr. Urs Leemann
Member of the Board of Directors

For the Paul Scherrer Institute – PSI, Villigen:

City: Villigen PSI

Date: 9.12.2020

[Signature]

Prof. Dr. Christian Rüegg,
Director PSI

[Signature]

Dr. Thierry Strässle,
Chief of Staff

Annex: abbreviations

AM	Advanced Manufacturing (SFA of the ETH Domain)
DCC	Data Coordination Center of SPHN
EC	Executive Committee of PHRT
ETH Domain	EAWAG, Empa, ETH Zurich EPF Lausanne, PSI, WSL
IAB	International Advisory Board (of SPHN)
iDoc	Interdisciplinary doctoral student Project
PI	Principal Investigator
PH	Personalized health
PHRT	Personalized Health and Related Technologies
PM	Personalized medicine
SC	Strategic Committee of PHRT
SERI	State Secretariat of Education, Research and Innovation (German: SBFi)
SDSC	Swiss Data Science Center (SFA of the ETH Domain)
SFA	Strategic Focus Area of the ETH Domain
SNSF	Swiss National Science Foundation
SPHN	Swiss Personalized Health Network
TPdF	Transition Postdoc Fellowship